Management of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
For patients with chronic fatigue syndrome presenting with post-exertional malaise, sleep disturbance, orthostatic intolerance, pain, and mood symptoms, implement activity pacing as the cornerstone intervention and avoid graded exercise therapy, while treating orthostatic intolerance with β-blockers (propranolol 10-20 mg four times daily) or midodrine (2.5-15 mg every 4 hours up to three times daily), and consider low-dose naltrexone for pain and neurological symptoms 1, 2, 1.
Core Management Principles
Activity Pacing (Primary Intervention)
Pacing is the most critical management strategy and involves deliberately managing energy resources to prevent post-exertional malaise 1, 3. This means:
- Patients must identify their energy envelope—the amount of activity they can sustain without triggering symptom worsening
- Activities should be planned during peak energy periods identified through daily/weekly symptom diaries
- Rest periods must be strategically scheduled before exhaustion occurs
- All non-essential activities should be postponed during moderate-to-severe symptom periods 4
Critical caveat: Exercise and graded exercise therapy are contraindicated—75% of patients worsen with physical activity, and less than 1% improve 1. This represents a fundamental shift from older recommendations.
Symptom-Specific Pharmacological Management
Orthostatic Intolerance/POTS
When patients experience excessive tachycardia (>30 bpm increase) upon standing with symptoms of lightheadedness, palpitations, or weakness 5:
First-line pharmacological options 2, 1:
- Propranolol: 10-20 mg four times daily (nonselective β-blocker reduces standing heart rate and improves exercise capacity)
- Midodrine: 2.5-15 mg every 4 hours up to three times daily (most beneficial for patients with hypotensive tendency)
- Pyridostigmine: Can be combined with β-blockers to reduce orthostatic tachycardia (avoid in patients with diarrhea; may help those with constipation)
- Fludrocortisone: For volume expansion when oral salt intake inadequate (monitor for edema, hypokalemia; avoid in migraine patients)
Non-pharmacological measures 1, 2, 1:
- Increase salt intake (8-10 grams daily)
- Increase fluid intake (2-3 liters daily)
- Compression stockings
- Intermittent IV normal saline bolus (1-2 L over 1-2 hours) as rescue therapy
Pain Management
Recommended pharmacological options 6:
- Low-dose naltrexone: Effective for pain, fatigue, and neurological symptoms in ME/CFS 1
- Serotonin-norepinephrine reuptake inhibitors (SNRIs): For pain and improved functional status 6
- Pregabalin: For pain treatment 6
- Gabapentin: Commonly used in practice 7
Avoid: NSAIDs for chronic pain related to ME/CFS 6. Strongly avoid: Long-term opioid use 6.
Sleep Disturbance
Address unrefreshing sleep through:
- Cognitive behavioral therapy for insomnia (CBT-I) as supportive intervention 4, 8
- Limit daytime naps to less than one hour to avoid disturbing nighttime sleep 4
- Minimize evening caffeine and other sleep-disrupting factors 9
Cognitive Dysfunction
Implement cognitive pacing alongside physical pacing 1:
- Break cognitive tasks into smaller segments
- Schedule cognitively demanding activities during peak energy periods
- Consider post-concussion syndrome protocols 1
Depression and Anxiety
Important distinction: These are often secondary to the chronic illness burden, not primary psychiatric conditions 10, 3.
Management approach:
- Evaluate whether mood symptoms are reactive to functional limitations
- Consider SNRIs if treating concurrent pain 6
- Tricyclic antidepressants may be used but evidence is limited 6, 7
- CBT should only be offered as supportive intervention, not as curative treatment 8
Additional Therapeutic Considerations
Supplements with Supporting Evidence
From ME/CFS literature 1:
- Coenzyme Q10: For fatigue
- D-ribose: For fatigue and mitochondrial support
- Vitamin D and B12: Commonly used (72.2% of patients report supplement use) 7
Immune Dysfunction
Consider intravenous immunoglobulin in consultation with immunologist for documented immune dysfunction 1.
Mast Cell Activation Symptoms
H1 and H2 antihistamines, particularly famotidine, may alleviate wide range of symptoms (though not curative) 1.
Critical Management Pitfalls to Avoid
Do not recommend graded exercise therapy—this is explicitly contraindicated and can cause severe, prolonged worsening 1, 8
Do not dismiss symptoms as purely psychological—ME/CFS is a multisystem neuroimmune disease with documented biological abnormalities including mitochondrial dysfunction, immune dysregulation, and endothelial dysfunction 1, 3
Do not delay diagnosis—ME/CFS can be diagnosed after 3 months of symptoms (not 6 months) to improve long-term outcomes 8
Do not use high-dose or long-acting β-blockers—these worsen fatigue and exercise tolerance; only low-dose, short-acting formulations are recommended 2
Monitoring and Follow-up
- Assess for concurrent conditions that may worsen fatigue: hypothyroidism, anemia, diabetes, medication side effects 4
- Monitor for autonomic dysfunction and sleep disturbance as treatable contributors 9
- Evaluate for low cortisol levels indicating hypothalamic-pituitary-adrenal axis dysfunction 1
- Screen for reactivated herpesviruses (EBV, HHV-6, CMV) which may require antiviral therapy 1
Educational Support
Patients and families require education about 10, 11, 3:
- The chronic nature of the illness (mean duration 5 years, range 1-16 years)
- Post-exertional malaise as the cardinal feature requiring activity modification
- The importance of remaining engaged in education/work to extent possible (best predictor of later functioning)
- Self-management strategies and symptom monitoring through daily logs
Prognosis: Approximately 20% will have significant restrictions after 10 years, emphasizing the importance of early, appropriate management to prevent deterioration 10.